Hims & Hers Health, Inc. Class A Common Stock (HIMS)

Raising debt increases the risk in Hims & Hers' stock.

Hims & Hers Health (NYSE: HIMS) shares are trading flat in Tuesday's pre-market as traders continue to digest its convertible notes offering.

Hims & Hers Health’s first quarter was marked by a significant strategic pivot in its weight loss business, which management described as a move to prioritiz...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including Hims & Hers Health (NYSE:HIMS) and its peer...

Hims & Hers continues growing rapidly, but shrinking margins and rising costs are beginning to test the company's long-term profitability story.

The stock continues to be very volatile.

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...

Hims & Hers Health posted a Q1 FY2026 double miss, with an EPS loss of $0.40 and revenue of $608.1 million, sending shares down more than 12% after hours.

Hims & Hers is unshaken by its earnings miss, with management promising even faster sales growth this year.

Telehealth company Hims & Hers Health (NYSE:HIMS) fell short of the market’s revenue expectations in Q1 CY2026 as sales rose 3.8% year on year to $608.1 mill...

Hims & Hers Health (NYSE:HIMS) reported first-quarter 2026 revenue growth and raised its full-year revenue outlook, while executives said a strategic shift in the company’s weight-loss business is creating short-term margin pressure and volatility in GAAP results. On the company’s earnings call

Hims HIMS Q1 2026 Earnings Call Transcript

Telehealth company Hims & Hers Health (NYSE:HIMS) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 3.8% year on year to $608.1 million. O...

Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting results this Monday after the bell. Here’s what to expect. Hims & Hers Health met analyst...

As Hims & Hers pivots to branded GLP-1s via a Novo Nordisk deal, all eyes are on the company’s May 11 earnings as investors look for sustained subscriber growth.

The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits.

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 4% in the afternoon session after the stock's momentum weakened as Amazon.com...

SpaceX is buying another AI company, but does this mean it can catch up to Google, Anthropic, or OpenAI?

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 9.6% in the afternoon session after JPMorgan initiated coverage on the comp...